Psychosocial influences on cancer incidence and progression

Harvard Review of Psychiatry

Volumn 4, Issue 1, 1996, Pages 10-26

  Spiegel, David ^a   Kato, Pamela M ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER INCIDENCE; CANCER RISK; CIRCADIAN RHYTHM; DEPRESSION; EMOTIONALITY; FEEDING BEHAVIOR; HUMAN; PERSONALITY; PRIORITY JOURNAL; PSYCHOSOCIAL ENVIRONMENT; REVIEW; RISK ASSESSMENT; RISK FACTOR; SOCIAL SUPPORT; STRESS;

EID: 0030012692     PISSN: 10673229     EISSN: None     Source Type: Journal    
DOI: 10.3109/10673229609030518     Document Type: Review

References (158)

1. Jensen AB. Psychosocial factors in breast cancer and their possible impact upon prognosis. Cancer Treat Rev 1991;18: 191-210.
2. Greer S, Morris T. Psychological attributes of women who develop breast cancer: a controlled study. J Psychosom Res 1975;19:147-53.
3. Antoni MH, Goodkin K. Host moderator variables in the promotion of cervical neoplasia; I: personality facets. J Psychosom Res 1988;32:327-38.
4. Lambley P. The role of psychological processes in the aetiology and treatment of cervical cancer: a biopsychological perspective. Br J Med Psychol 1993;66:43-60.
5. Bernhard J, Ganz PA. Psychosocial issues in lung cancer patients (part 1). Chest 1991;99:216-23.
6. Kune GA, Kune S, Watson LF, Bahnson CB. Personality as a risk factor in large bowel cancer: data for the Melbourne Colorectal Cancer Study. Psychol Med 1991;21:43-60.
7. Hilakivi-Clarke L, Rowland J, Clarke R, Lippman ME. Psychosocial factors in the development and progression of breast cancer. Breast Cancer Res Treat 1993;29:141-60.
8. Cohen S, Wills TA. Stress, social support, and the buffering hypothesis. Psychol Bull 1985;98:310-57.
9. Goodkin K, Antoni MH, Helder L, Sevin B. Psychoneuroimmunological aspects of disease progression among women with human papillomavirus-associated cervical dysplasia and human immunodeficiency virus type 1 co-infection. Int J Psychiatry Med 1993;23:119-48.
10. Sarason IG, Levine HM, Basham RB, Sarason BR. Assessing social support: the Social Support Questionnaire. J Pers Soc Psychol 1983;44:127-39.
11. Herbert TB, Cohen S. Stress and immunity in humans: a meta-analytic review. Psychosom Med 1993;55:364-79.
12. Holmes TH, Rahe RH. The Social Readjustment Rating Scale. J Psychosom Res 1967;11:213-8.
13. Ewertz M. Bereavement and breast cancer. Br J Cancer 1986;53:701-3.
14. Fournier D. Tumorwachstum als Kriterium der Malignität. In: Frommhold W, Gerhardt P, editors. Das Mammakarzinom. Stuttgart: Thieme, 1982.
15. Hatch MC, Wallenstein S, Beyea J, Nieves JW, Susser M. Cancer rates after the Three Mile Island nuclear accident and proximity of residence to the plant. Am J Public Health 1991;81:719-24.
16. Forsén A. Psychosocial stress as a risk for breast cancer. Psychother Psychosom 1991;55:176-85.
17. Geyer S. Life events prior to manifestation of breast cancer: a limited prospective study covering eight years before diagnosis. J Psychosom Res 1991;35:355-63.
18. Brown GW, Harris T. The Bedford College Life-Events and Difficulty Schedule directory of contextual threat ratings of events. London: Bedford College, University of London, 1978.
19. Shekelle RB, Raynor WJ Jr, Ostfeld AM, Garron DC, Bieliauskas LA, Liu SC, et al. Psychological depression and 17-year risk of death from cancer. Psychosom Med 1981;43: 117-25.
20. Persky VW, Kempthorne-Rawson J, Shekelle RB. Personality and risk of cancer: 20-year follow-up of Western Electric Study. Psychosom Med 1987;49:435-49.
21. Fox BH. Depressive symptoms and risk of cancer [Editorial]. JAMA 1989;262:1231.
22. Kaplan GA, Reynolds P. Depression and cancer mortality and morbidity: prospective evidence from the Alameda County Study. J Behav Med 1988;11:1-13.
23. Hahn RC, Petitti DB. Minnesota Multiphasic Personality Inventory-rated depression and the incidence of breast cancer. Cancer 1988;61:845-8.
24. Zonderman AB, Costa PT, McCrae RR. Depression as a risk for cancer morbidity and mortality in a nationally representative sample. JAMA 1989;262:1191-5.
25. Radloff LS. The CES-D Scale: a self-report depression scale for research in the general population. J Appl Psychol Meas 1977;1:385-401.
26. Vogt T, Pope C, Mullooly J, Hollis J. Mental health status as a predictor of morbidity and mortality: a 15-year follow-up of members of a health maintenance organization. Am J Public Health 1994;84:227-31.
27. Srole L, Langner TS, Michael ST. Mental health in the metropolis: the Midtown Manhattan Study. New York: McGraw-Hill, 1962.
28. Hilakivi-Clarke L, Wright A, Lippman ME. DMBA-induced mammary tumor growth in rats exhibiting increased or decreased ability to cope with stress due to early postnatal handling or antidepressant treatment. Physiol Behav 1993; 54:229-36.
29. Levenson JL, Bemis C. The role of psychological factors in cancer onset and progression. Psychosomatics 1991;32:124-32.
30. Spiegel D, Sands SH. Psychological influences on metastatic disease progression. In: Gorelik EL, editor. Metastasis/dissemination. Dordrecht, Netherlands: Kluwer, 1989.
31. Derogatis LR, Abeloff MD, Melisaratos N. Psychological coping mechanisms and survival time in metastatic breast cancer. JAMA 1979;242:1504-8.
32. Greer S, Morris T, Pettingale KW. Psychological response to breast cancer: effect on outcome. Lancet 1979;2:785-7.
33. Greer S. Psychological response to cancer and survival. Psychol Med 1991;21:43-9.
34. Temoshok L. Biopsychosocial studies on cutaneous malignant melanoma: psychosocial factors associated with prognostic indicators, progression, psychophysiology, and tumor-host-response. Soc Sci Med 1985;20:833-40.
35. Stavraky KM, Donner AP, Kincade JE, Stewart MA. The effect of psychosocial factors on lung cancer mortality at one year. J Clin Epidemiol 1988;41:75-82.
36. Stein S, Linn MW, Stein EM. Psychological correlates of survival in nursing home cancer patients. Gerontologist 1989;29:224-8.
37. Parkes CM. Accuracy of predictions of survival in later stages of cancer. BMJ 1972;2:29-31.
38. Schwarz R, Geyer S. Social and psychological differences between cancer and noncancer patients: cause or consequence of the disease? Psychother Psychosom 1984;41:195-9.
39. Kukull WA, McCorkle R, Driever M. Symptom distress, psychosocial variables, and survival from lung cancer. J Psychosoc Oncol 1986;4:29-41.
40. Weisman AD, Worden JW. The existential plight in cancer: significance of the first 100 days. Int J Psychiatry Med 1976-77;7:1-15.
41. Dean C, Surtees PG. Do psychological factors predict survival in breast cancer? J Psychosom Res 1989;33:561-9.
42. Lazarus RS. The cost and benefits of denial. In: Monat A, Lazarus RS, editors. Stress and coping. New York: Columbia University Press, 1985:154-73.
43. Kreitler S, Chaitchik S, Kreitler H. Repressiveness: cause or result of cancer? Psycho Oncol 1993;2:43-54.
44. Berkman LF, Syme SL. Social networks, host resistance, and mortality: a nine-year follow-up study of Alameda County residents. Am J Epidemiol 1979;109:186-204.
45. House JS, Landis KR, Umberson D. Social relationships and health. Science 1988;241:540-5.
46. Smith CE, Fernengel K, Holcroft C, Gerald K. Meta-analysis of the associations between social support and health outcomes. Ann Behav Med 1994;16:352-62.
47. Goodwin JS, Hunt WC, Key CR, Samet JM. The effect of marital status on stage, treatment and survival of cancer patients. JAMA 1987;258:3125-30.
48. Reynolds P, Kaplan GA. Social connections and risk for cancer: prospective evidence from the Alameda County Study. Behav Med 1990;16:101-10.
49. Ell K, Nishimoto R, Mediansky L, Mantell J, Hamovitch M. Social relations, social support and survival among patients with cancer. J Psychosom Res 1992;36:531-41.
50. Hislop TG, Waxier NE, Coldman AJ, Elwood JM, Kan L. The prognostic significance of psychosocial factors in women with breast cancer. J Chronic Dis 1987;40:729-35.
51. Waxler-Morrison N, Hislop TG, Mears B, Kan L. Effects of social relationships on survival for women with breast cancer: a prospective study. Soc Sci Med 1991;33:177-83.
52. Maunsell E, Jacques B, Deschenes L. Social support and survival among women with breast cancer. Presented at the annual Psycho-oncology meeting, Memorial- Sloan Kettering Cancer Center, October, 1993.
53. Neale AV. Racial and marital status influences on 10 year survival from breast cancer. J Clin Epidemiol 1994;47:475-83.
54. Levenson RW, Carstensen LL, Gottman JM. The influence of age and gender on affect, physiology, and their interrelations: a study of long-term marriages. J Pers Soc Psychol 1994;67: 56-68.
55. Levy SM, Herberman RB, Lippman M, D'Angelo R, Lee J. Immunological and psychosocial predictors of disease recurrence in patients with early-stage breast cancer. Behav Med 1991;17:67-75.
56. Lazarus RS, Folkman S. Stress, appraisal, and coping. New York: Springer, 1984.
57. Ramirez AJ, Craig TK, Watson JP, Fentiman IS, North WR, Rubens RD. Stress and relapse of breast cancer. BMJ 1989; 298:291-3.
58. Barraclough J, Pinder P, Cruddas M, Osmond C, Taylor I, Perry M. Life events and breast cancer prognosis. BMJ 1992;304:1078-81.
59. Stroebe MS, Stroebe W. The mortality of bereavement: a review. In: Stroebe MS, Stroebe W, Hansson RO, editors. Handbook of bereavement: theory, research, and interventions. New York: Cambridge University Press, 1993:175-95.
60. Kaprio J, Koskenvuo M, Rita H. Mortality after bereavement: a prospective study of 95,647 widowed persons. Am J Public Health 1987;77:283-7.
61. Jones DR, Goldblatt PO. Cause of death in widow(er)s and spouses. J Biosoc Sci 1987;19:107-21.
62. Tornling G, Gustavsson P, Hogstedt C. Mortality and cancer incidence in Stockholm fire fighters. Am J Ind Med 1994;25: 219-28.
63. Spiegel D. Psychosocial intervention in cancer. J Natl Cancer Inst 1993;85:1198-205.
64. Spiegel D, Bloom JR, Yalom ID. Group support for patients with metastatic cancer: a randomized prospective outcome study. Arch Gen Psychiatry 1981;38:527-33.
65. Rosengren A, Tibblin G, Wilhelmsen L. Self-perceived psychological stress and incidence of coronary artery disease in middle-aged men. Am J Cardiol 1991;68:1171-5.
66. Perissin L, Zorzet S, Rapozzi V, Paoletti D, Giraldi T. Seasonal dependency of the effects of experimental stressors on tumor metastasis on mice bearing Lewis lung carcinoma. Chronobiologia 1994;21:99-103.
67. Baltrusch HJ, Stangel W, Titze I. Stress, cancer and immunity: new developments in biopsychosocial and psychoneuroimmunologic research. Acta Neurol 1991;13:315-27.
68. Hill DR, Kelleher K, Shumaker SA. Psychosocial interventions in adult patients with coronary heart disease and cancer: a literature review. Gen Hosp Psychiatry 1992;14(6 suppl):28S-42S.
69. Spiegel D, Bloom JR, Kraemer HC, Gottheil E. Effect of psychosocial treatment on survival of patients with metastatic breast cancer. Lancet 1989;2:888-901.
70. Richardson JL, Shelton DR, Krailo M, Levine AM. The effect of compliance with treatment on survival among patients with hematologic malignancies. J Clin Oncol 1990;8:356-64.
71. Fawzy FI, Fawzy NW, Hyun CS, Elashoff R, Guthrie D, Fahey JL, et al. Malignant melanoma: effects of an early structured psychiatric intervention, coping, and affective state on recurrence and survival 6 years later. Arch Gen Psychiatry 1993;50:681-9.
72. Gellert GA, Maxwell RM, Siegel BS. Survival of breast cancer patients receiving adjunctive psychosocial support therapy: a 10-year follow-up study. J Clin Oncol 1993;11: 66-9.
73. Morgenstern H, Gellert GA, Walter SD, Ostfeld AM, Siegel BS. The impact of a psychosocial support program on survival with breast cancer: the importance of selection bias in program evaluation. J Chronic Dis 1984;37:273-82.
74. Ilnyckyj A, Farber J, Cheang MC, Weinerman B. An 11 yr follow up of a randomized study of support groups (gps) in cancer patients (pts) [Abstract]. Clin Invest Med 1993;16(4 suppl):B95.
75. Grossarth-Maticek R, Eysenck HJ. Creative novation behaviour therapy as a prophylactic treatment for cancer and coronary heart disease; part I: description of treatment. Behav Res Ther 1991;29:1-16.
76. Grossarth-Maticek R, Schmidt P, Vetter H, Arundt S. Psychotherapy research in oncology. In: Steptoe A, Mathews A, editors. Health care and human behavior. London: Academic, 1984:325-41.
77. Eysenck HJ, Grossarth-Maticek R. Creative novation behaviour therapy as a prophylactic treatment for cancer and coronary heart disease; part II: effects of treatment. Behav Res Ther 1991;29:17-31.
78. Fox BH. Quandaries created by unlikely numbers in some of Grossarth-Maticek's studies. Psychol Inquiry 1991;2:242-7.
79. Van der Ploeg HM. What a wonderful world it would be: a reanalysis of some of the work of Grossarth-Maticek. Psychol Inquiry 1991;2:280-5.
80. Mulder CL, Van der Pompe G, Spiegel D, Antoni MH, De Vries MJ. Do psychosocial factors influence the course of breast cancer: a review of recent literature, methodological problems and future directions. Psycho Oncol 1992;1:155-67.
81. Stones MJ, Dornan B, Kozma A. The prediction of mortality in elderly institution residents. J Gerontol 1989;44:72-9.
82. Andersen BL, Kiecolt-Glaser JK, Glaser R. A biobehavioral model of cancer stress and disease course. Am Psychol 1994; 49:389-404.
83. Butrum RP, Clifford CK, Lanza E. NCI dietary guideline: rationale. Am J Clin Nutr 1988;48:888-95.
84. Klaish LA. Relationship of body size with breast cancer. J Clin Oncol 1984;2:287-93.
85. Albanes D. Total calories, body weight, and tumor incidence in mice. Cancer Res 1987;47:1987-92.
86. Eberlein T, Simon R, Fisher S, Lippman M. Height, weight and risk of breast cancer relapse. Breast Cancer Res Treat 1985;5:81-6.
87. Zumoff B, Gorzynski JG, Katz JL, Weiner H, Levin J, Holland J, et al. Nonobesity at the time of mastectomy is highly predictive of 10-year disease-free survival in women with breast cancer. Anticancer Res 1982;2:59-62.
88. Garland M, Willett WC, Manson JE, Hunter DJ. Antioxidant micronutrients and breast cancer. J Am Coll Nutr 1993;12: 400-11.
89. Schatzkin A, Longnecker MP. Where are we now and where do we go from here? Cancer 1994;74:1101-10.
90. Yirmiya R, Ben-Eliyahu S, Gale RP, Shavit Y, Liebeskind JC, Taylor AN. Ethanol increases tumor progression in rats; possible involvement of natural killer cells. Brain Behav Immun 1992;6:74-86.
91. Bagenal FS, Easton DF, Harris E, Chilvers CE, McElwain TJ. Survival of patients with breast cancer attending Bristol Cancer Help Center. Lancet 1990;336:606-10.
92. Hodgson LA. Why do we need sleep? Relating theory to nursing practice. J Adv Nurs 1991;16:1503-10.
93. Strang P, Qvarner H. Cancer-related pain and its influence on quality of life. Anticancer Res 1990;10:109-12.
94. Silberfarb PM, Hauri PJ, Oxman TE, Schnurr P. Assessment of sleep in patients with lung cancer and breast cancer. J Clin Oncol 1993;11:997-1004.
95. Everson CA. Sustained sleep deprivation impairs host defense. Am J Physiol 1993;265:1148-54.
96. Itano J, Tanabe P, Lum J, Lamkin L, Rizzo E, Weiland M, et al. Compliance and noncompliance in cancer patients. Prog Clin Biol Res 1983;120:483-95.
97. Glass A, Wieand HS, Fisher B, Redmond C, Lerner H, Wolter J, et al. Acute toxicity during adjuvant chemotherapy for breast cancer: the National Surgical Adjuvant Breast and Bowel Project (NSABP) experience from 1717 patients receiving single and multiple agents. Cancer Treat Rep 1981;65: 363-76.
98. Laszlo J, Lucas VS, Huang R. Emesis as a critical problem in chemotherapy. N Engl J Med 1981;305:948-9.
99. Lee YT. Adjuvant chemotherapy (CMF) for breast carcinoma: patient's compliance and total dose achieved. Am J Clin Oncol 1983;6:25-30.
100. Wilcox PM, Fetting JF, Nettesheim KM, Abeloff MD. Anticipating vomiting in women receiving cyclophosphamide, methotrexate, and 5-FU (CMF) adjuvant chemotherapy for breast carcinoma. Cancer Treat Rep 1982;66:1601-4.
101. Marcus AC, Crane LA, Kaplan CP, Reading AE, Savage E, Gunning J, et al. Improving adherence to screening follow-up among women with abnormal Pap smears: results from a large clinic-based trial of three intervention strategies. Med Care 1992;30:216-30.
102. Lerman C, Miller SM, Scarborough R, Hanjani P, Nolte S, Smith D. Adverse psychologic consequences of positive cytologic cervical screening. Am J Obstet Gynecol 1991;165:658-62.
103. Hoagland AC, Morrow GR, Bennett JM, Carnrike CL Jr. Oncologists' views of cancer patient noncompliance. Am J Clin Oncol 1983;6:239-44.
104. Steckel SB. Predicting, measuring, implementing and following up on patient compliance. Nurs Clin North Am 1982;17: 491-8.
105. Lerman C, Hanjani P, Caputo C, Miller S, Delmoor E, Nolte S, et al. Telephone counseling improves adherence to colposcopy among lower-income minority women. J Clin Oncol 1992;10:330-3.
106. Given BA, Given CW. Compliance among patients with cancer. Oncol Nurs Forum 1989;16:97-103.
107. Lerman C, Rimer B, Blumberg B, Cristinzio S, Engstrom PF, MacElwee N, et al. Effects of coping style and relaxation on cancer chemotherapy side effects and emotional responses. Cancer Nurs 1990;13:308-15.
108. Ley P. The psychology of compliance. In: Osborne DJ, Gruenberg MM, Eiser JR, editors. Research in psychology and medicine, vol 2. London: Academic, 1979:187-95.
109. Bandura A. Self-efficacy: toward a unifying theory of behavior change. Psychol Rev 1977;84:191-215.
110. Ferguson K, Bole GG. Family support, health beliefs, and therapeutic compliance in patients with rheumatoid arthritis. Patient Couns Health Educ 1979;1:101-5.
111. Beck NC, Parker JC, Frank RG, Geden EA, Kay DR, Gamache M, et al. Patients with rheumatoid arthritis at high risk for noncompliance with salicylate treatment regimens. J Rheumatol 1988;15:1081-4.
112. Taylor SE, Lichtman RR, Wood JV. Attributions, beliefs about control, and adjustment to breast cancer. J Pers Soc Psychol 1984;46:489-502.
113. Wyszynski AA. Managing noncompliance in the 'difficult' medical patient. Psychother Psychosom 1990;54:181-6.
114. Rose RM. Overview of endocrinology of stress. In: Brown GM, Koslow SH, Reichlin S, editors. Neuroendocrinology and psychiatric disorder. New York: Raven, 1984:95-122.
115. McDaniel JS, Musselman DL, Porter MR, Reed DA, Nemeroff CB. Depression in patients with cancer: diagnosis, biology, and treatment. Arch Gen Psychiatry 1995;52:89-99.
116. Chrousos GP, Gold PW. The concepts of stress and stress system disorder. JAMA 1992;267:1244-52.
117. Nemeroff CB, Widerlov E, Bissette G, Walleus H, Karlsson I, Eklund K, et al. Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients. Science 1984;226:1342-4.
118. Sapolsky RM, Krey LC, McEwen BS. The adrenocortical axis in the aged rat: impaired sensitivity to both fast and delayed feedback inhibition. Neurobiol Aging 1986;7:331-5.
119. Sapolsky RM, Donnelly TM. Vulnerability to stress-induced tumor growth increases with age in rats: role of glucocorticoids. Endocrinology 1985;117:662-5.
120. Folkman J, Langer R, Linhardt R, Haudenschild C, Taylor S. Angiogenesis inhibition and tumor regression caused by heparin or a heparin fragment in the presence of cortisone. Science 1983;221:719-25.
121. Riley V. Psychoneuroendocrine influences on immunocompetence and neoplasia. Science 1981;212:1100-9.
122. Rowse GJ, Weinberg J, Bellward GD, Emerman JT. Endocrine mediation of psychosocial stressor effects on mouse mammary tumor growth. Cancer Lett 1992;65:85-93.
123. Godden J, Leake R, Kerr DJ. The response of breast cancer cells to steroid and peptide growth factors. Anticancer Res 1992;12:1683-8.
124. Malarkey WB, Kennedy M, Allred LE, Milo G. Physiological concentrations of prolactin can promote the growth of human breast tumor cells in culture. J Clin Endocrinol Metab 1983; 56:673-7.
125. Shafie S, Brooks SC. Effect of prolactin on growth and the estrogen receptor level of human breast cancer (MCF-7). Cancer Res 1977;37:792-9.
126. Sternberg EM, Wilder RL, Gold PW, Chrousos GP. A defect in the central component of the immune system-hypothalamic-pituitary-adrenal axis feedback loop is associated with susceptibility to experimental arthritis and other inflammatory diseases. Ann N Y Acad Sci 1990;594:289-92.
127. Felten SY, Olschowka J. Noradrenergic sympathetic innervation of the spleen: tyrosine hydroxylase (TH)-positive nerve terminals from synaptic-like contacts on lymphocytes in the splenic white pulp. J Neurosci Res 1987;18:37-48.
128. Drucker D, McLaughlin J. Adrenocortical dysfunction in acute medical illness. Crit Care Med 1986;14:789-91.
129. Parker LN, Levin ER, Lifrak ET. Evidence for adrenocortical adaptation to severe illness. J Clin Endocrinol Metab 1985; 60:947-52.
130. Ozasa H, Kita M, Inoue T, Mori T. Plasma dehydroepiandrosterone-to-cortisol ratios as an indicator of stress in gynecologic patients. Gynecol Oncol 1990;37:178-82.
131. Bulbrook RD, Hayward JL. Abnormal urinary steroid excretion and subsequent breast cancer: a prospective study in the Island of Guernsey. Lancet 1967;1:519-22.
132. Irwin M, Daniels M, Risch SC, Bloom E, Weiner H. Plasma cortisol and natural killer cell activity during bereavement. Biol Psychiatry 1988;24:173-8.
133. Cohen S, Tyrrell DA, Smith PA. Psychological stress and susceptibility to the common cold. N Engl J Med 1991;325: 606-12.
134. Levine S, Coe C, Weiner SG. Psychoneuroendocrinology of stress: a psychobiological perspective. In: Brush FR, Levine S, editors. Psychoendocrinology. San Diego: Academic, 1989: 341-77.
135. Ader R, Felten D, Cohen N. Interactions between the brain and the immune system. Annu Rev Pharmacol Toxicol 1990; 30:561-602.
136. Romano TA, Felten SY, Felten DL, Olschowka JA. Neuropeptide-Y innervation of the rat spleen: another potential immunomodulatory neuropeptide. Brain Behav Immun 1991;5: 116-31.
137. Madden KS, Felten SY, Felten DL, Sundaresan PR, Livnat S. Sympathetic neural modulation of the immune system; I: depression of T cell immunity in vivo and in vitro following chemical sympathectomy. Brain Behav Immun 1989;3:72-89.
138. Lorton D, Bellinger DL, Felten SY, Felten DL. Substance P innervation of spleen in rats: nerve fibers associate with lymphocytes and macrophages in specific compartments of the spleen. Brain Behav Immun 1991;5:29-40.
139. Strauman TJ. Self-discrepancies in clinical depression and social phobia: cognitive structures that underlie emotional disorders? J Abnorm Psychol 1989;98:5-14.
140. Strauman TJ, Lemieux AM, Coe CL. Self-discrepancy and natural killer cell activity: immunological consequences of negative self-evaluation. J Pers Soc Psychol 1993;64:1042-52.
141. Bovbjerg DH, Redd WH, Maier LA, Holland JC, Lesko LM, Niedzwiecki D, et al. Anticipatory immune suppression and nausea in women receiving cyclic chemotherapy for ovarian cancer. J Consult Clin Psychol 1990;58:153-7.
142. Villa ML, Ferrario E, Bergamasco E, Bozzetti F, Cozzaglio L, Clerici E. Reduced natural killer cell activity and IL-2 production in malnourished cancer patients. Br J Cancer 1991; 63:1010-4.
143. Bovbjerg D. Psychoneuroimmunology and cancer. In: Holland JC, Rowland JH, editors. Handbook of psychooncology: psychological care of the patient with cancer. New York: Oxford University Press, 1989:727-54.
144. Rosenberg S, Lotze M. Cancer immunotherapy using interleukin-2 and interleukin-2-activated lymphocytes. Annu Rev Immunol 1986;4:681-709.
145. Herberman R. Natural killer (NK) cells: characteristics and possible role in resistance against tumor growth. In: Reif AE, Mitchell MS, editors. Immunity to cancer. Orlando: Academic, 1985:217-29.
146. Levy SM, Herberman RB, Whiteside T, Sanzo K, Lee J, Kirkwood J. Perceived social support and tumor estrogen/progesterone receptor status as predictors of natural killer cell activity in breast cancer patients. Psychosom Mod 1990;52:73-85.
147. Fawzy FI, Kemeny ME, Fawzy NW, Elashoff R, Morton D, Cousins N, et al. A structured psychiatric intervention for cancer patients; II: changes over time in immunological measures. Arch Gen Psychiatry 1990;47:729-35.
148. Zanker KS, Kroczek R. Looking along the track of the psychoneuroimmunologic axis for missing links in cancer progression. Int J Sports Med 1991;12(suppl 1):S58-62.
149. Shavit Y, Terman GW, Martin FC. Stress, opioid peptides, the immune system, and cancer. J Immunol 1985;135(2 suppl): 834s-7s.
150. Ben-Eliyahu S, Yirmiya R, Liebeskind JC, Taylor AN, Gale RP. Stress increases metastatic spread of a mammary tumor in rats: evidence for mediation by the immune system. Brain Behav Immun 1991;5:193-205.
151. Stutman O. Immunological surveillance revisited. In: Reif AE, Mitchell MS, editors. Immunity to cancer. Orlando: Academic, 1985:323-45.
152. Doll R, Kinlen L. Immunosurveillance and cancer: epidemiological evidence. BMJ 1970;4:420-2.
153. Kennedy S, Kiecolt-Glaser JK, Glaser R. Immunological consequences of acute and chronic stressors: mediating role of interpersonal relationships. Br J Med Psychol 1988;61:77-85.
154. Kiecolt-Glaser JK, Fisher L, Ogrocki P, Stout JC, Speicher CE, Glaser R. Marital quality, marital disruption, and immune function. Psychosom Med 1987;49:13-34.
155. Kiecolt-Glaser JK, Kennedy S, Malkoff S, Fisher L, Speicher CE, Glaser R. Marital discord and immunity in males. Psychosom Med 1988;50:213-29.
156. Kiecolt-Glaser JK, Garner W, Speicher C, Penn GM, Holliday J, Glaser R. Psychosocial modifiers of immunocompetence in medical students. Psychosom Med 1984;46:7-14.
157. Pennebaker JW, Kiecolt-Glaser JK, Glaser R. Disclosure of traumas and immune function: health implications for psychotherapy. J Consult Clin Psychol 1988;56:23-45.
158. Lechin F, Van der Dijs B, Vitelli-Florez G, Lechin-Baez S, Azocar J, Cabrera A, et al. Psychoneuroendocrinological and immunological parameters in cancer patients: involvement of stress and depression. Psychoneuroendocrinology 1990;15: 435-51.